Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Acquired by Janus Henderson Group PLC

Janus Henderson Group PLC raised its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 47.3% in the third quarter, HoldingsChannel reports. The firm owned 6,813,163 shares of the company’s stock after acquiring an additional 2,189,339 shares during the period. Janus Henderson Group PLC owned approximately 0.07% of Dyne Therapeutics worth $244,755,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its holdings in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after buying an additional 669 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Dyne Therapeutics in the 3rd quarter valued at approximately $34,000. US Bancorp DE raised its stake in Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after acquiring an additional 1,212 shares in the last quarter. Values First Advisors Inc. bought a new stake in Dyne Therapeutics during the 3rd quarter valued at $62,000. Finally, KBC Group NV boosted its position in Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after acquiring an additional 751 shares during the period. Institutional investors own 96.68% of the company’s stock.

Insider Transactions at Dyne Therapeutics

In related news, Director Dirk Kersten sold 79,411 shares of the stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $36.45, for a total value of $2,894,530.95. Following the completion of the sale, the director now directly owns 234,127 shares of the company’s stock, valued at approximately $8,533,929.15. This represents a 25.33 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jason P. Rhodes sold 782 shares of Dyne Therapeutics stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $33.10, for a total value of $25,884.20. Following the transaction, the director now directly owns 15,962 shares in the company, valued at approximately $528,342.20. This trade represents a 4.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 176,257 shares of company stock valued at $6,193,718 over the last ninety days. Corporate insiders own 20.77% of the company’s stock.

Dyne Therapeutics Price Performance

DYN opened at $28.17 on Wednesday. The business has a fifty day simple moving average of $31.56 and a 200-day simple moving average of $35.48. Dyne Therapeutics, Inc. has a fifty-two week low of $10.33 and a fifty-two week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, equities analysts expect that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently weighed in on DYN. HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Oppenheimer restated an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. Stifel Nicolaus increased their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a report on Friday, August 16th. JPMorgan Chase & Co. cut Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $43.00 to $35.00 in a report on Thursday, October 24th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $53.00 price target on shares of Dyne Therapeutics in a research note on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $50.82.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.